### **Overview** Indegene Ltd is a digital-first, technology-enabled life sciences commercialization and transformation partner serving pharmaceutical, biotech, and medical device companies globally. Founded in 1998, the company specializes in integrating **deep healthcare domain expertise** with **cutting-edge technology**, particularly **Artificial Intelligence (AI)** and **Generative AI (GenAI)**, to modernize operations across the drug development and commercialization lifecycle. Operating from 19 offices and 9 global hubs across North America, Europe, and Asia, Indegene employs over **5,000 professionals**, including over **26% with healthcare qualifications (e.g., MD, PhD, BPharm)**. The company is uniquely positioned at the intersection of life sciences and digital innovation, offering end-to-end solutions in commercial, medical, regulatory, R&D, and clinical operations. --- ### **Core Strategic Focus** Indegene’s growth is anchored in three key strategies: 1. **Deepening enterprise relationships** with the world's top 20 biopharmaceutical companies through cross-selling, up-selling, and geographic expansion. 2. **Expanding the client base** into mid-tier and emerging biotech firms (ranked 21–100), which represent a fast-growing segment. 3. **Entering new market segments** and scaling emerging business verticals, particularly in AI-driven commercialization, clinical solutions, and transformation consulting. Over **65% of revenue** comes from the top 20 global biopharma companies (down from 78% in FY21 due to diversification), with 73 active clients as of FY25—41 of which generate over $1 million in annual revenue. --- ### **Recent Growth Initiatives & Strategic Acquisitions** Indegene is actively pursuing an **inorganic growth strategy** through targeted, value-accretive acquisitions to expand domain capabilities and technology offerings. Key acquisitions include: - **BioPharm Communications LLC & Addressable Health LLC (Oct 2025):** Acquired for **$104 million** (plus $2 million for working capital) to strengthen U.S.-based **omnichannel media**, **AdTech**, and **precision marketing** capabilities. - Combined revenue (proforma) of **$373.8 million** and **EBITDA of $74.4 million**. - Brings **1.8M webinar records**, **3M programmatic ad records**, and **300M+ exposure events** to enhance HCP targeting. - Enables hyper-targeted "push" and "pull" engagement models and deep therapeutic penetration (oncology, rare diseases, ophthalmology). - **MJL Communications Group Ltd (Apr 2025):** UK-based healthcare advertising agency acquired for **£398 million** (including earnouts) to enhance **creative storytelling**, **brand strategy**, and **patient engagement** capabilities in Europe. - **Trilogy Writing & Consulting GmbH (2024):** German-based medical writing firm enhancing **regulatory submissions** and **clinical documentation** services globally. - **CultHealth LLC (2022):** Integrated into the **Tectonic** offering—a strategic initiative to move upstream in the marketing value chain by combining creative, AI, and medical expertise. These acquisitions underscore a broader strategy of **vertical integration**—from brand strategy (upstream) to media execution and distribution (downstream)—creating a full-funnel, data-driven partner for life sciences clients. --- ### **Technology & AI Leadership** Indegene has positioned itself as a **front-runner in GenAI adoption** for life sciences, recognized by **Everest Group** and **HFS Research** as a **Leader in Generative AI**. #### **Cortex: Enterprise GenAI Platform (Launched FY24–25)** - A **purpose-built**, **life sciences-specific GenAI platform** designed for enterprise-scale adoption. - Features: - **Modular, no-code interface** for domain experts to build AI agents using natural language. - **Multi-agent orchestration**, **LLM-agnostic agents**, and enterprise-grade **governance, security, and compliance**. - Embedded **25+ years of operational expertise** through codified knowledge graphs. - Supported by the **‘GenAI @ Work’** initiative training all 5,000+ employees in GenAI. - Strategic collaboration with **Microsoft** to leverage **Azure OpenAI**, **Copilot**, and **Microsoft Fabric** for accelerated AI adoption. #### **AI-Driven Solutions & Platforms:** - **SME Workbench:** No-code GenAI tool enabling rapid client CoE development. - **GenAI Applications:** - **Content Super App:** Unified creation, personalization, and compliance of commercial content. - **MLR Automation:** Reduces medical-legal-regulatory review time via GenAI. - **Medical Writing Platform:** Drafts regulatory documents using GenAI (e.g., PSURs). - **Adverse Event Management:** Uses AI to process unstructured safety data rapidly. - **Digital Rep Equivalence:** AI-powered engagement model generating **12% of revenue** through virtual HCP outreach. #### **Data & Analytics Infrastructure** - **Tandem Platform:** Expands **HCP database to 3 million profiles** (from 1.8M), enriched with **20+ years of engagement data** from 300M+ exposure events and 15M+ engagements. - **FusionArchitecture:** Proprietary integration layer combining AI, real-world data, and enterprise workflows for contextual, compliant automation. - **Invisage™:** AI-powered omnichannel platform enabling hyper-personalized engagement via email, social media, and virtual representatives. --- ### **Service Offerings & Business Segments** Indegene serves clients across four core segments: | **Segment** | **Focus** | **Revenue Contribution** | **Key Solutions** | |------------|----------|--------------------------|-------------------| | **Enterprise Commercial Solutions (ECS)** | Multi-brand, multi-country digital marketing | **56%** (Creative & Content Services) | Tectonic, Omnichannel Marketing, Digital Asset Mgmt | | **Omnichannel Activation Solutions** | Brand-level U.S./Europe precision engagement | ~20% | BioPharm media capabilities, Addressable Health | | **Enterprise Medical Solutions (EMS)** | Regulatory, medical affairs, pharmacovigilance | **28%** | MLR Automation, Aggregate Reporting, RWE | | **Enterprise Clinical Solutions** | Clinical trials, data management, recruitment | — | NEXT Patient Recruitment, partnerships (CliniOps, Datavant) | - **ECS + EMS account for ~85%** of total revenue, characterized by **recurring, long-term engagements** with high retention. - Emerging **Clinical Solutions** are gaining traction through: - Partnership with **Datavant** to accelerate rare disease trials using real-world data. - Collaboration with **CliniOps** for integrated clinical trial operations. --- ### **Global Presence & Operational Model** - **9 hubs, 19 offices** in **USA, UK, Germany, Switzerland, India, China, Japan, Mexico, Canada, Spain, Ireland, Singapore**. - **100% of top 20 global biopharma companies** are clients. - Subsidiaries in key regions support localized delivery and talent acquisition. - **India remains strategic**—recent expansions in **Hyderabad** (Nov 2024) and **Pune** (Sep 2025)—leveraging the country’s strong talent pool in medical and technology domains. --- ### **Growth Trajectory & Financial Highlights** - **Q2 FY25 Revenue:** INR 6,868 million (+8% YoY, +1.5% QoQ). - **H1 FY25 YoY Growth:** 9.7%. - **Client Growth:** Increased from 44 (2020) to 73 (FY25), with 41 generating $1M+ annually. - **Revenue per Client:** Largest client generates **$42 million**, with potential to grow to **$100M+**. - **Deal Momentum (FY26):** - 1 deal > $5M ACV (EU pharma). - 3 deals between $1.5M–$3M ACV with mid-tier pharma. - 5 new deals (Feb 2025) valued $2M–$4M each, going live Q2. --- ### **Differentiation & Competitive Advantage** - **Only digital-first partner** offering integrated services across **commercial, medical, regulatory, and clinical** functions. - **Techno-Domain Convergence:** 600+ technologists work alongside doctors and PhDs, with **domain expertise embedded into AI workflows**. - **Platform-Based Delivery:** Avoids point solutions with scalable, integrated platforms (Cortex, NEXT, Tandem). - **Full Commercialization Lifecycle Coverage:** From pre-launch planning to post-market support and real-world evidence.